Shanghai Jmt-bio Inc.

This phase 2 study tests whether a new drug called JSKN003 works better than the current standard therapy for people with HER2-positive breast cancer that has returned or spread. About 60 adults who have not had prior treatment for advanced disease will receive either JSKN003 or …

This early-phase study tests a new drug called SYS6090 combined with standard chemotherapy or other drugs in about 600 people with advanced lung cancer (non-small cell or small cell). The goal is to see if the combinations are safe and if they can shrink tumors. The trial is not …

This Phase 3 trial tests a new drug called JSKN003 against standard treatments for people with advanced HER2-positive colorectal cancer that has not responded to three common chemotherapies. About 123 participants will be randomly assigned to receive either JSKN003 or a standard …

This study tests a new drug called KN026, combined with chemotherapy and an immunotherapy (enlonstobart), as a first treatment for people with HER2-positive advanced stomach cancer that cannot be removed by surgery. About 490 participants will be split into groups to compare this…